Novo Nordisk dans l'actualité
Solutions de santé pour le diabète
Tamtam a trouvé 20 articles récents sur Novo Nordisk.
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
- Novo Nordisk loses another patent behind Ozempic and Wegovy drugs
- Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
- Novo skifter ud i topledelsen
- Your Ozempic Prescription May Come With a Surprising Bonus: Slower Aging
- Novo Nordisk stock target cut at Citi on lack of margin growth
- Aktien er nede med 22 pct. i år: Her er analytikernes dom over Novo-aktien
- Novo Nordisk introduces new diabetes treatment option in Thailand
- Hackers had access to Novo Nordisk systems for at least 47 days
- Novo goes on deal spree amid semaglutide patent expiries
- QMs samarbejde med Novo Nordisk og Qpurpose
- Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
- Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
- Novo Nordisk Probes Patient Priorities in German Hemophilia A Study
- Novo Nordisk (NVO) Pulls Back Sharply, Is It A Bargain?
- Novo flags FDA hemophilia review extension tied to manufacturing site corrections
- FDA delays decision on Novo's hemophilia drug
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S : JP Morgan is Neutral
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Novo Nordisk ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires